Drug Pipeline
New drugs to treat migraine are approaching approval and could bring relief for many patients, but they portend higher costs. Ongoing monitoring and appropriate utilization... More
Feature
“Drug Costs”
13 result(s)
Cost Management
Payors are projected to save on per-member-per-month costs from strategic formulary removals designed to help mitigate the effect of high-cost and hyperinflationary drugs More
Briefing
Cost Management
GAO Reinforces Positive Impact of PBMs in Part D
New GAO report shows that rebates negotiated on behalf of payors may help control premiums and provides further proof of the value PBMs bring to payors and members. More
Commentary
Public Policy
Proposed HHS rule would eliminate rebates PBMs negotiate for Part D plans and MCOs, and may eventually affect all plans. Manufacturers would retain 15% of rebates currently... More
Briefing
Cost Management
The Guaranteed Net Cost model guarantees average net spend per prescription, after discounts and rebates, for each distribution channel. More
Feature
Cost Management
CVS Health responded to the Administration's Blueprint on lowering drug costs and highlighted what the company does to control costs. We also recommended things the... More
Commentary
Cost Management
Paying-for-performance is where health care is headed. CVS Health’s new performance network will deliver unit cost savings, as well as improved clinical outcomes to help lower... More
Briefing
Drug Pipeline
The market for migraine medications is ripe for growth due to a large patient population with an unmet clinical need. Four investigational medications known CGRP inhibitors will... More
Feature
Cost Management
Value-based management can only deliver on their promise of incremental cost-savings if the right guardrails are in place to ensure appropriate utilization and management. More
Briefing
Cost Management
Value-based management seeks go beyond a static, pre-set price tag to uncover true value for drugs and better health for patients. More
Briefing